Difference between revisions of "Amsacrine (Amsidine)"
Jump to navigation
Jump to search
m |
m |
||
| Line 12: | Line 12: | ||
*[[Acute myeloid leukemia, pediatric]] | *[[Acute myeloid leukemia, pediatric]] | ||
| + | ==History of changes in EMA indication== | ||
| + | *1982-04-23: EURD | ||
==Also known as== | ==Also known as== | ||
*'''Code names:''' CI-880, SN-11841 | *'''Code names:''' CI-880, SN-11841 | ||
| Line 31: | Line 33: | ||
[[Category:Orphan drug]] | [[Category:Orphan drug]] | ||
| + | [[Category:EMA approved in 1982]] | ||
[[Category:Health Canada approved drugs]] | [[Category:Health Canada approved drugs]] | ||
Revision as of 18:50, 12 June 2023
General information
Class/mechanism: Synthetic acridine-derivate. Exact mechanism unclear; amsacrine binds to DNA by intercalation and external electrostatic binding, which inhibits DNA synthesis and causes DNA fragmentation.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
Diseases for which it is used
History of changes in EMA indication
- 1982-04-23: EURD
Also known as
- Code names: CI-880, SN-11841
- Generic names: acridinyl anisidide, AMSA, Cain's acridine, m-AMSA
- Brand names: Amekrin, Amsa P-D, Amsidine, Amsidyl, Lamasine